Latest Industry News & Trends

Optos Launches the Silverstone RGB Advanced Retinal Imaging System

UK-based Optos announced Oct. 15 that it had launched its next-generation Silverstone RGB system for retinal imaging. The device is designed to allowclinicians to capture, visualize, and analyze pa...

EssilorLuxottica Acquires Screening Software Company RetinAI

Eyewear conglomerate EssilorLuxottica announced Oct. 15 that it would acquire Swiss company Ikerian, operating under the RetinAI brand. RetinAI develops tools to collect, process, and grade large-s...

OcuSciences’ OcuMet Beacon Retinal Imager Gains CE Marking

OcuSciences, of Ann Arbor, Michigan, announced Oct. 15 that its OcuMet Beacon retinal imager had gained CE marking under the European Medical Device Regulation. The device gained US FDA 510(k) clea...

US FDA Approves Celltrion’s Aflibercept Biosimilar Branded Eydenzelt

South Korea’s Celltrion announced Oct. 9 that the US FDA had approved Eydenzelt, an aflibercept (Eylea) biosimilar. Eydenzelt (aflibercept-boav 40 mg/mL solution for injection) is indicated for wet...

RetinalGenix Partners with Genotyping Lab on Disease Detection Through the Eye

RetinalGenix Technologies announced Oct. 1 that it would collaborate with genotyping lab RGEN, of West Virginia, to advance the early detection of neurodegenerative, systemic, and retinal diseases....

Ashvattha Names Bob Dempsey as Interim CEO

Ashvattha Therapeutics, of Redwood City, California, announced Oct. 14 that it had appointed Robert J. Dempsey as interim chief executive officer. The move follows the company’s release of positive...

Teresa Puthussery, PhD, OD, Named 2025 MacArthur Fellow

Teresa Puthussery, PhD, a neurobiologist and optometrist, has been named one of the 22 MacArthur Fellows for 2025. The MacArthur Foundation, based in Chicago, Illinois, annually selects fellows who...

Oculis Accelerates Privosegtor Toward Pivotal Trials in Neuro-ophthalmology

Swiss company Oculis announced Oct. 6 that it will advance Privosegtor into a pivotal program for two indications in neuro-ophthalmology following a positive meeting with the US FDA. Privosegtor is...

Regulators in China Accept BLA for DME Candidate from Santen, RemeGen

Japan’s Santen Pharmaceutical and partner RemeGen announced Sept. 30 that China’s Center for Drug Evaluation had accepted the biologic license application (BLA) for retinal treatment candidate RC28...

US FDA Gives Green Light to Phase I/II Trial of Complement’s GA Gene Therapy Candidate

Complement Therapeutics announced Oct. 8 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of CTx001, a gene ...

Outlook Meets with US FDA, Plans to Resubmit BLA for Lytenava This Year

Outlook Therapeutics reported Sept. 29 that it had met with the US FDA regarding its latest rejection of the company’s biologics license application (BLA) for Lytenava, an ophthalmic formulation of...

Visufarma Becomes Part of India’s Lupin Limited

Visufarma BV, of the Netherlands, will become part of India-based Lupin Limited following Visufarma’s acquisition by a Lupin subsidiary. Visufarma has been owned by GHO Capital Partners, of London,...

US FDA Accepts Idebenone NDA for Priority Review, Sets PDUFA Date of Feb. 28, 2026

Chiesi announced Sept. 22 that the US FDA had accepted its new drug application (NDA) for oral idebenone to treat Leber hereditary optic neuropathy (LHON). Regulators set a Prescription Drug User F...

Regulators in Japan Approve Aflibercept (Eylea) Biosimilar from Alvotech and Fuji

Iceland’s Alvotech announced Sept. 19 that its commercialization partner in Japan, Fuji Pharma, has received marketing approval for AVT06, a biosimilar to Eylea (aflibercept), from the Japanese Min...

Alcon and BVI Launch New Vitrectomy Systems at Euretina Congress in Paris

Equipment manufacturers launched new vitrectomy systems or instruments at the 2025 Euretina congress, held Sept. 4-7 at the Palais des Congrès in Paris. They had a large audience. Euretina set an a...

NEI Awards U. of Houston Researchers $3.6 Million to Investigate Vision-Critical Gene

A research team at the University of Houston was awarded more than $3.6 million from the National Eye Institute to investigate a gene that causes blinding retinal diseases when mutated. When workin...

US FDA Grants Fast Track Status to Sanofi’s Wet AMD Gene Therapy Candidate

France’s Sanofi announced Sept. 11 that the US FDA had granted fast track designation to SAR402663, a one-time IVT gene therapy candidate for wet age-related macular degeneration. SAR402663 deliver...

Ophthalmic Company Revenue Down 1.9 Percent in Q2-2025 as Multiple Firms Report Declines

Ophthalmic manufacturer revenue in Q2-2025 totaled $11.7 billion. Revenue decreased 1.9 percent from the same quarter in 2024 and increased 6.3 percent from Q1-2025. The total includes Market Scope...

Ophthalmologists Report 2.2 Percent Increase in Q2-2025 Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 2.2 percent in Q2-2025 compared with the same quarter in 2024, according to Market Scope’s latest survey. Year-over-year performanc...

Annexon Aims to Make Difference in GA by Focusing on Neuroprotection

Excitement is growing around vonaprument (previously called ANX007), the drug that Annexon Biosciences is developing to treat geographic atrophy (GA). The international Phase III trial of the poten...

Regulatory Panel in Japan Recommends Izervay for Approval in GA

A Japanese panel has recommended approval for Astellas Pharma’s avacincaptad pegol (known in the US as Izervay) to slow the progression of geographic atrophy (GA), according to a Pharma Japan repor...

Kriya Leads Latest Ophthalmic Fundraising with $320 Million in Series D

Kriya, of Durham, North Carolina, led recent ophthalmic fundraising efforts with a $320 million Series D round to fund its pipeline of gene therapy candidates. Financing announced in the past four ...

US FDA Again Rejects Outlook’s Lytenava for Wet AMD, Citing Lack of Efficacy Evidence

Outlook Therapeutics reported Aug. 28 that the US FDA had issued a complete response letter rejecting the company’s resubmitted biologics license application (BLA) for Lytenava, an ophthalmic formu...

PDUFA Dates for Ophthalmic Drug Candidates, September 2025

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

Sandoz’ Deal with Regeneron Will Bring Enzeevu to Market in US by Q4-2026

Swiss drugmaker Sandoz announced Sept. 9 that it had reached an agreement with Regeneron to resolve all patent disputes related to Sandoz’ FDA-approved Eylea (aflibercept) biosimilar, branded in th...

Clinical Trial Updates for Ophthalmic Candidates, September 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

2025-2027 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Euretina Presentations Included Surprises on Vitreous Cutters, PBM Treatment

Doctors who attend the annual Euretina congress often hear paper presentations similar to those at the American Society of Retina Specialists meeting, but sessions also provide important difference...

Two European Retina Innovation Meetings, Two Audiences

Euretina once again scheduled its European Innovation Spotlight to go head-to-head with the Ophthalmology Futures Retina Forum. Both were held Sept. 3 in Paris, France. The two events seem similar ...

Moran Celebrates Approval of AI Tech to Help Time Injections for Wet AMD

The John A. Moran Eye Center is celebrating European regulatory approval of AI technology that assists ophthalmologists in timing intravitreal injections in wet age-related macular degeneration (AM...

Emerging Companies Pursuing Ophthalmic Indications, September 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Weekly Surgeon Poll, September 2025

September 2025 Ophthalmic News Briefs

The UK-based National Institute for Health and Care Excellence (NICE) announced Sept. 11 that it had approved idebenone (marketed as Raxone by Chiesi Pharmaceuticals) for the treatment of Leber her...

Kwangdong Licenses Ocugen’s RP Gene Therapy Candidate for Korea

Ocugen announced Sept. 15 that it had reached a licensing agreement with Kwangdong Pharmaceutical for exclusive Korean rights to OCU400—Ocugen’s modifier gene therapy candidate for retinitis pigmen...

Sandoz’ Deal with Regeneron Will Bring Enzeevu to Market in US No Later than Q4-2026

Swiss drugmaker Sandoz announced Sept. 9 that it had reached an agreement with Regeneron to resolve all patent disputes related to Sandoz’ FDA-approved Eylea (aflibercept) biosimilar, branded in th...

UK’s NICE Approves First Treatment for Leber Hereditary Optic Neuropathy (LHON)

The UK-based National Institute for Health and Care Excellence (NICE) announced Sept. 11 that it had approved idebenone (marketed as Raxone by Chiesi Pharmaceuticals) for the treatment of Leber her...

Formycon, Klinge License Eylea Biosimilar to Horus for France, Other European Countries

German companies Formycon and Klinge Biopharma announced Sept. 17 that they had reached a deal with France-based Horus Pharma to license their Eylea (aflibercept) biosimilar for France and other se...

Alteogen Gains EU Approval for Eylea Biosimilar Eyluxvi

South Korea’s Alteogen announced Sept. 17 that the European Commission had granted marketing authorization for Eyluxvi (formerly ALT-L9), its biosimilar to Eylea (aflibercept 2 mg). The biosimilar ...

Xpanceo and Intra-Ker Unveil Corneal Implant that Projects Images onto Retina

Xpanceo, of the United Arab Emirates, and Intra-Ker, of Italy, announced Sept. 3 successful proof of concept of their intracorneal implant, designed to restore vision in patients with corneal blind...

Nanoscope’s MCO-010 Gains Five EMA Orphan Designations and US FDA RMAT Status

Nanoscope Therapeutics announced Sept. 2 that the European Medicines Agency (EMA) had granted orphan designations to MCO-010 (sonpiretigene isteparvovec) across five categories of retinal dystrophi...

4DMT Promotes Julie Clark, MD, to Chief Medical Officer

4D Molecular Therapeutics announced Sept. 2 that it had promoted Julie Clark, MD, to chief medical officer. Clark joined 4DMT in July 2025 as senior vice president, clinical research and developmen...

BVI Launches Virtuoso Dual-Function Cataract/Vitrectomy System in Europe

BVI Medical announced Sept. 3 that it had unveiled its new Virtuoso dual-function cataract/vitrectomy surgical platform in Europe, expanding the company’s offerings beyond IOLs and consumables. BVI...

Roche Gains CE Marking for Port Delivery Platform, Branded Contivue in Europe

Swiss drugmaker Roche announced Sept. 4 that it had gained CE marking for its Port Delivery Platform, a refillable ranibizumab implant, which will be known as Contivue in Europe. The approval compr...

Former LumiThera Diagnostic Business Relaunches as OpZira After Alcon Deal

LumiThera’s former ophthalmic diagnostic business has been spun off and relaunched as OpZira, the new company announced Sept. 3. As part of Alcon’s acquisition of the Valeda Light Delivery System f...

Regulatory Panel in Japan Recommends Izervay for Approval in GA

A Japanese panel has recommended approval for Astellas Pharma’s avacincaptad pegol (known in the US as Izervay) to slow the progression of geographic atrophy (GA), according to a Pharma Japan repor...

LambdaVision Secures NASA Award to Advance Manufacturing of Artificial Retina in Low-Earth Orbit

LambdaVision announced Sept. 4 that it had secured an award from the National Aeronautics and Space Administration (NASA) to further develop the low-Earth orbit manufacturing process for its artifi...

US FDA Again Rejects Outlook’s Lytenava for Wet AMD, Citing Lack of Efficacy Evidence

Outlook Therapeutics reported Aug. 28 that the US FDA had issued a complete response letter rejecting the company’s resubmitted biologics license application (BLA) for Lytenava, an ophthalmic formu...

Quarterly Ophthalmic Revenue Roundup for Santen, Lumibird, Biogen, and Xbrane

Japan’s Santen Pharmaceutical reported Aug. 7 that its revenue for the quarter ended June 30, 2025, the first quarter of its fiscal year, was ¥68.7 billion ($475.6 million, converted on June 30, 20...

Manufacturer Inspection Report Delays Two Eylea HD Target Action Dates 

Regeneron announced Aug. 20 that the US FDA had extended the target action dates to Q4-2025 for two Eylea HD (aflibercept 8 mg) submissions. Reports from a recent inspection of a third-party manufa...

US FDA Grants Fast Track Status to Aldeyra’s ADX‑2191 (Methotrexate) for RP

Aldeyra Therapeutics announced Aug. 19 that the US FDA had granted its fast track designation to ADX‑2191 (methotrexate intravitreal injection) for retinitis pigmentosa (RP). The candidate also has...

US FDA Grants RMAT Status to VeonGen’s Gene Therapy Candidate in Stargardt

Germany’s VeonGen Therapeutics announced Aug. 21 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to VG801, its gene therapy candidate for Stargardt disease and...

Alvotech, Advanz Gain EU Approval for Eylea Biosimilar Under Brand Name Mynzepli

Alvotech and partner Advanz Pharma announced Aug. 21 that the European Commission had granted marketing authorization for their Eylea (aflibercept 2 mg) biosimilar under the brand name Mynzepli. Th...

Q2-2025 Ophthalmic Revenue Roundup for Alcon, Carl Zeiss Meditec, Opus, and Outlook

Alcon reported Aug. 19 that its Q2-2025 net sales totaled $2.6 billion, a 4 percent increase (+3 percent cc) over $2.5 billion in Q2-2024. Surgical net sales for implantables, consumables, and equi...

ASRS Meeting Returns Surgery to the Forefront of Discussion

Guarav Shah, MD, program chair for the 2025 annual meeting of the American Society of Retina Specialists (ASRS), opened the conference with an important announcement. “We have to recalibrate what w...

Boehringer Ingelheim, Palatin to Collaborate on Melanocortin Agonist for Retina

Boehringer Ingelheim and Palatin Technologies will collaborate to develop a therapy for retinal diseases in a deal worth up to $320 million for Palatin, the companies announced Aug. 18. Palatin’s p...

Santen Licenses RemeGen’s Retinal Candidate for Greater China, Asian Countries

RemeGen announced Aug. 18 that Santen China, a subsidiary of Japan’s Santen Pharmaceutical, had licensed retinal treatment candidate RC28-E for Greater China and certain other Asian countries. Reme...

US FDA Gives Green Light to Phase I/II Trial of Opus’ BEST1 Gene Therapy Candidate

Opus Genetics announced Aug. 18 that the US FDA had cleared its investigational new drug (IND) application for OPGx-BEST1, a gene therapy candidate targeting bestrophin-1 (BEST1)-related inherited ...

Nanoscope Targets Sight Restoration Instead of Blindness Prevention

Ashish Patel, PhD, MBA, calls blind people “the most underserved population” in ophthalmology. Patel, senior vice president for sales and marketing at Nanoscope Therapeutics, said other drug compan...

US CMS Issues J-Code for Encelto, Q-Code for Yesafili for Billing Payers

The US Centers for Medicare and Medicaid Services (CMS) issued a J-code for Neurotech’s Encelto and a Q-code for Biocon Biologics’ Yesafili during Q2-2025. The codes take effect Oct. 1, 2025. In ad...

CMS Proposes Lower Physician Payments in 2026, Higher HOPD and ASC Fees

US ophthalmologists are gaining some clarity on what their reimbursement for treating Medicare patients may look like in 2026. Documents published by the Centers for Medicare and Medicaid Services ...

Sustainability Movement Gains Traction, Impacts Growth in Reusable Instruments

In recent years, the world’s largest ophthalmic surgical societies have expressed increasing concern over the environmental impact of operating room waste generated annually by the world’s 50 milli...

Methotrexate Has ‘Avastin Moment’ at ASRS Meeting

Christopher Riemann, MD (US), was stunned when he initially saw the results from the first preplanned interim safety analysis of the Phase II FIXER trial on preventing proliferative vitreoretinopat...

ASRS Sessions Highlight Value of Amniotic Membrane in Retinal Surgery

The use of human amniotic membrane in vitreoretinal surgery was discussed in several sessions at the American Society of Retina Specialists’ 2025 meeting. Presentations suggest that this material w...

Speakers at ASRS Meeting Lament Dwindling Access to Operating Room

Access to the operating room (OR) was a hot topic at the 2025 meeting of the American Society of Retina Specialists. The majority of retina surgeons said access to the OR was an issue. Forty-nine p...

Cencora Steps into Major Role at ASRS Meeting Following Acquisition

The 2025 ASRS scientific meeting was a first for Cencora as an operator of clinical trials, but not for its subsidiary Retina Consultants of America (RCA). Cencora (formerly AmerisourceBergen), bet...

Ocugen Leads Latest Ophthalmic Fundraising with $20 Million Offering

Ocugen led recent ophthalmic fundraising efforts with a $20 million registered direct offering to advance its clinical gene therapy pipeline in retina. Financing announced in the past four weeks to...

Boehringer Ingelheim and Re-Vana Sign Potential $1 Billion Collaboration Deal

Boehringer Ingelheim and Re-Vana Therapeutics will collaborate to develop extended-release therapies for eye diseases in a deal worth potentially more than $1 billion for Re-Vana, the companies ann...

Topcon Acquires Retinal Screening Platform to Improve Bidirectional Referrals

Topcon Healthcare reported July 31 that it had acquired Intelligent Retinal Imaging Systems (IRIS), a Pensacola, Florida-based developer of cloud-based retinal screening technology. No financial de...

Clinical Trial Updates for Ophthalmic Candidates, August 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Emerging Companies Pursuing Ophthalmic Indications, August 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

August 2025 Ophthalmic News Briefs

Glaukos announced during its earnings call on July 30 that it had acquired Mobius Therapeutics, of St. Louis, Missouri, whose lead compound, Mitosol, is the only FDA approved ophthalmic formulation...

Q2-2025 Ophthalmic Revenue Roundup for Tarsus, Immunocore, Harrow, ANI, Sight Sciences, and Iridex

Tarsus Pharmaceuticals, of Irvine, California, reported Aug. 6 that its Q2-2025 Xdemvy net product revenue was $102.7 million, a 152 percent increase over $40.8 million in Q2-2024. The company said...

EMA Selects Annexon’s GA Candidate for Regulatory Pilot Program

Annexon announced Aug. 7 that vonaprument (formerly ANX007), the company’s treatment candidate for geographic atrophy, was among the programs selected by the European Medicines Agency (EMA) to part...

Moran Celebrates Approval of AI Tech to Help Time Injections for Wet AMD

The John A. Moran Eye Center is celebrating European regulatory approval of AI technology that assists ophthalmologists in timing intravitreal injections in wet age-related macular degeneration (AM...

First Commercial Procedure Performed with Encelto, Only FDA-Approved Treatment for MacTel

Neurotech Pharmaceuticals, of Cumberland, Rhode Island, announced Aug. 11 the first commercial surgical procedure for Encelto, the only US FDA-approved treatment for macular telangiectasia (MacTel)...

US FDA Grants Fast Track Status to AAVantgarde’s Stargardt Candidate

Italy’s AAVantgarde Bio announced Aug. 12 that the US FDA had granted fast track status to AAVB-039, its gene therapy candidate for Stargardt disease. AAVB-039 aims to address the underlying geneti...

Q2-2025 Ophthalmic Revenue Roundup for Regeneron, Amgen, AbbVie, Hoya, and Ocular Therapeutix

Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2025 US revenue for Eylea HD and Eylea 2 mg was $1.15 billion, a 25 percent decrease from $1.53 billion in Q2-2024. Eylea HD accounted...

​US CMS Issues J-Code for Encelto, Q-Code for Yesafili for Billing Payers

The US Centers for Medicare and Medicaid Services (CMS) issued a J-code for Neurotech’s Encelto and a Q-code for Biocon Biologics’ Yesafili during Q2-2025. The codes take effect Oct. 1, 2025. In ad...

Regenxbio Plans Pivotal Program for DR Gene Therapy, Amends Deal with AbbVie

Regenxbio announced Aug. 7 that it was planning a pivotal program for its suprachoroidal gene therapy candidate in diabetic retinopathy (DR)—along with a corresponding amendment to its collaboratio...

Topcon Healthcare Acquires Retinal Screening Platform to Improve Bidirectional Referrals

Topcon Healthcare reported July 31 that it had acquiredIntelligent Retinal Imaging Systems (IRIS), a Pensacola, Florida-based developer of cloud-based retinal screening technology. No financial det...

EMA Grants Orphan Designation to Aldeyra’s Methotrexate Injection for RP

Aldeyra Therapeutics announced July 24 that the European Medicines Agency (EMA) had granted orphan designation for ADX-2191 (methotrexate intravitreal injection) for inherited retinal dystrophies o...

Aeye Health Appoints Pamela F. Gallin, MD, as Chief Medical Officer

Aeye Health announced July 31 that it had appointed Pamela F. Gallin, MD, as its chief medical officer. Gallin is a clinical professor of ophthalmology in pediatrics at the Morgan Stanley Children’...

Q2-2025 Ophthalmic Revenue Roundup for Roche, Bausch + Lomb, Apellis, Glaukos, and Astellas

Swiss company Roche reported July 24 that Vabysmo sales for Q2-2025 were CHF 1.05 billion ($1.3 billion, converted June 30, 2025), a 19 percent increase over CHF 947 million in Q2-2024. Roche said ...

CMS Proposes Lower Physician Payments in 2026, Higher HOPD and ASC Fees

US ophthalmologists are gaining some clarity on what their reimbursement for treating Medicare patients may look like in 2026. Documents published by the Centers for Medicare and Medicaid Services ...

Boehringer Ingelheim and Re-Vana Sign Potential $1 Billion Collaboration Deal

Boehringer Ingelheim and Re-Vana Therapeutics will collaborate to develop extended-release therapies for eye diseases in a deal worth potentially more than $1 billion for Re-Vana, the companies ann...

Aflibercept Biosimilar Candidate from Alteogen Gains Positive CHMP Opinion

South Korea’s Alteogen announced July 28 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended approval for Eyluxvi (ALT-L9), its proposed biosi...

Exonate Plans Phase IIb Trial of Retinal Eye Drop Candidate in NPDR

British company Exonate announced July 29 that it planned a Phase IIb clinical trial for lead compound EXN407, an eye drop candidate targeting retinal vascular diseases, in patients with non-prolif...

Unity Board Dissolves Company, Ending Research Targeting Senescent Cells

Unity Biotechnology’s board agreed on June 27 to dissolve the South San Francisco, California, company after evaluating strategic alternatives. The Nasdaq delisted Unity’s stock on July 9. Both mov...

Bioeq Licenses Lucentis Biosimilar to Bio Usawa for Sub-Saharan Africa

Swiss company Bioeq announced July 1 that it had licensed its Lucentis (ranibizumab) biosimilar to African biotech company Bio Usawa for marketing in sub-Saharan Africa under the brand name BioUcen...

Regulators in Canada Approve Xipere for Uveitic Macular Edema

Clearside Biomedical announced July 23 that Health Canada had approved Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use in uveitic macular edema. Bausch + Lomb has lice...

Novartis Reports Q2-2025 Lucentis Revenue of $173 Million

Novartis reported July 17 that its Q2-2025 Lucentis revenue outside the US was $173 million, a 37 percent decline (-39 percent cc) from $275 million in Q2-2024. The Swiss company said sales decline...

Beacon Licenses Abeona’s AAV204 Capsid for Select Ophthalmic Indications

Beacon Therapeutics has exercised its option to license Abeona Therapeutics’ AAV204 capsid for potential gene therapies for select ophthalmic indications, the companies announced July 1. Under the ...

US FDA Grants Fast Track Status to Sanofi’s GA Gene Therapy Candidate

France’s Sanofi announced July 16 that the US FDA had granted fast track designation to SAR446597, its gene therapy candidate for geographic atrophy (GA). SAR446597, designed for one-time intravitr...

Outlook Therapeutics Appoints Bob Jahr as CEO

Outlook Therapeutics announced July 1 that it had appointed Bob Jahr as chief executive officer. Jahr will also take a seat on Outlook’s board, the company said. Lawrence A. Kenyon, who had served ...

Alcon to Acquire LumiThera and Its Photobiomodulation Device for Dry AMD

Alcon announced July 7 that it intended to acquire LumiThera and its photobiomodulation (PBM) device that targets early and intermediate dry age-related macular degeneration (AMD). No financial det...

Harrow Secures US Rights to Retinal Biosimilars Byooviz and Opuviz

Harrow announced July 17 that it had secured exclusive US commercial rights to Samsung Bioepis’ FDA-approved ophthalmology biosimilars—Byooviz (ranibizumab-nuna) and Opuviz (aflibercept-yszy). No f...

ForSight Leads Latest Ophthalmic Fundraising with $125 Million in Series B

Israel’s ForSight Robotics led recent ophthalmic fundraising efforts with $125 million in Series B funding as it prepares its robotic cataract surgery system for human trials. Financing announced i...

Retina Researchers Urge J&J to File for Approval of XLRP Gene Therapy Despite Failed Trial

Investigators in the Phase III LUMEOS trial, with backing from the Foundation Fighting Blindness, issued a statement June 6 exhorting Johnson & Johnson to file for US FDA approval of bota-vec, a ge...

EyeDura Wins Two Octane Awards for Sustained-Release Eye Drop Platform

EyeDura Therapeutics earned the judges’ top award during Octane’s capital and growth company presentations, which spotlighted early-stage, high-potential ophthalmic ventures. The company was a favo...

Baruch Kuppermann, MD, PhD, Receives 2025 Roger Steinert, MD, Legacy Award

Baruch Kuppermann, MD, PhD, was honored at the Octane meeting as the recipient of the 2025 Roger Steinert, MD, Legacy Award, which recognizes significant leadership, innovation, and enduring contri...

Clearside Explores Strategic Alternatives, Transitions Workforce

Clearside Biomedical reported July 17 that it was exploring strategic alternatives to continue advancing its suprachoroidal space delivery platform and ophthalmic pipeline, while transitioning all ...

OpRegen’s Phase I/IIa Trial in GA Shows Mean Improvement in VA Through 36 Months

Lineage Cell Therapeutics reported on June 23 that patients with geographic atrophy who were treated with OpRegen cell therapy in a Phase I/IIa clinical study showed mean improvement in visual acui...

Clinical Trial Updates for Ophthalmic Candidates, July 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Emerging Companies Pursuing Ophthalmic Indications, July 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Iridex Reports Start of UK Trial Using MicroPulse with Anti-VEGF Injections in DME

Iridex reported June 24 that an independent, investigator-led UK study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy in diabetic macular edema (DME) had enrolled its first pat...

PDUFA Dates for Ophthalmic Drug Candidates, July 2025

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

July 2025 Ophthalmic News Briefs

Hoya Vision Care announced June 2 that it had acquired Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. Financial...

Harrow Secures US Rights to Retinal Biosimilars Byooviz and Opuviz

Harrow announced July 17 that it had secured exclusive US commercial rights to Samsung Bioepis’ FDA-approved ophthalmology biosimilars—Byooviz (ranibizumab-nuna) and Opuviz (aflibercept-yszy). No f...

Clearside Explores Strategic Alternatives, Transitions Workforce

Clearside Biomedical reported July 17 that it was exploring strategic alternatives to continue advancing its suprachoroidal space delivery platform and ophthalmic pipeline, while transitioning all ...

Nanoscope Initiates Rolling BLA Submission for Optogenetic RP Candidate

Nanoscope Therapeutics announced July 14 that it had initiated a rolling biologics license application (BLA) submission to the US FDA for MCO-010, an ambient-light-activatable optogenetic monothera...

US FDA Gives Green Light to Trial of AAVantgarde’s Stargardt Gene Therapy Candidate

Italy’s AAVantgarde Bio announced July 15 that the US FDA had cleared the investigational new drug (IND) application for AAVB-039, its gene therapy candidate for Stargardt disease. The company said...

Alcon to Acquire LumiThera and Its Photobiomodulation Device for Dry AMD

Alcon announced July 7 that it intended to acquire LumiThera and its photobiomodulation (PBM) device that targets early and intermediate dry age-related macular degeneration (AMD). No financial det...

EU Regulators Approve Extended Six-Month Treatment Interval for Eylea 8 mg

German drugmaker Bayer announced June 27 that European regulators had granted a label extension for Eylea (aflibercept) 8 mg with extended treatment intervals of up to six months in wet age-related...

Alcon Unity VCS Dual-Function System Gains Approval in Canada

Alcon announced July 8 that its dual-function Unity Vitreoretinal Cataract System (VCS) had gained market approval from Health Canada. Commercial launch in Canada is expected in early 2026, the com...

Biocon Gains Approval in Canada for Yesafili, a Biosimilar to Eylea

India’s Biocon Biologics announced June 27 that Health Canada regulators had approved Yesafili, an aflibercept (Eylea) biosimilar, for wet age-related macular degeneration, macular edema secondary ...

Aflibercept Biosimilar Candidate from Alvotech Gains Positive CHMP Opinion

Alvotech and partner Advanz Pharma announced June 23 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended approval for AVT06, Alvotech’s propos...

Iridex Reports Start of UK Trial Using MicroPulse with Anti-VEGF Injections in DME

Iridex reported June 24 that an independent, investigator-led UK study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy in diabetic macular edema (DME) had enrolled its first pat...

OpRegen’s Phase I/IIa Trial in GA Shows Mean Improvement in VA Through 36 Months

Lineage Cell Therapeutics reported on June 23 that patients with geographic atrophy who were treated with OpRegen cell therapy in a Phase I/IIa clinical study showed mean improvement in visual acui...

Donor Gives $40M to Ophthalmology Department at CU Anschutz in Colorado 

An anonymous donor has given a $40 million gift for eye research to the Department of Ophthalmology at the University of Colorado (CU) AnschutzMedical Campus in Aurora, Colorado, the school announc...

Children’s Hospital Los Angeles Receives $12M Gift to Expand Cell, Gene Therapies

Children’s Hospital Los Angeles reported May 21 that it had received a $12 million gift from Alfred E. Mann Charities to establish a cell and gene therapy research endowment and a shorter-term fund...

Alcon Unity Cataract and Dual-Function Systems Gain Approval in Brazil

Alcon announced June 12 that its dual-function Unity Vitreoretinal Cataract System (VCS) and stand-alone Unity Cataract System (CS) had gained market approval from the Brazilian Health Regulatory A...

Zilia Gains Approval in Canada for its Fundus Camera With Ocular Oximetry

Quebec-based device maker Ziliareported June 19 that its Zilia Ocular device, a fundus camera that enables ocular oximetry, had gained approval from Health Canada. The company said it plans to laun...

Scottish Regulators Endorse Outlook’s Lytenava for NHS Scotland Use in Wet AMD

Outlook Therapeutics announced June 10 that the Scottish Medicines Consortium had recommended Lytenava (bevacizumab gamma) for use within its National Health Service system, NHS Scotland, for the t...

ARVO Sets Tone for AI-Focused Week With Avatar at Keynote Speech

The 2025 meeting of the Association for Research in Vision and Ophthalmology (ARVO) exceeded atten-dance expectations despite uncertainties sparked by US funding restrictions. The 10,915 attendees ...

Ophthalmic Company Revenue in Q1-2025 Down 2.1 Percent as Multiple Firms Report Declines

Ophthalmic manufacturer revenue in Q1-2025 totaled $11.0 billion. Revenue decreased 2.1 percent from the same quarter in 2024 and decreased 8.1 percent from Q4-2024. The total includes Market Scope...

Ophthalmologists Report 3.0 Percent Decrease in Q1-2025 Procedure Volume

US ophthalmologists reported that ophthalmic procedures decreased 3.0 percent in Q1-2025 compared with the same quarter in 2024, according to Market Scope’s latest survey. Year-over-year performanc...

Talks on Pharma Reforms Cloud Future of Europe’s Health Care Market

The European Council—made up of the heads of the European Union’s member states—on June 4 advanced its position on pharmaceutical reforms, teeing up negotiations with the European Parliament and Co...

Select US FDA Approvals and Clearances in May 2025

The US FDA’s ophthalmic device division granted clearance to one company’s technology using the 510(k) pathway in May 2025, according to the agency’s database. Heidelberg Engineering gained clearan...

Regenxbio Leads Latest Ophthalmic Fundraising with $150 Million Royalty Sale

Regenxbio led recent ophthalmic fundraising efforts with a $150 million sale of future non-ophthalmic royalties to Healthcare Royalty (HCRx). Financing announced in the past four weeks totaled $535...

Gore Launches Silicone-Free Plunger for Ophthalmic Prefilled Syringes

Materials company W.L. Gore & Associates announced June 3 the commercial launch of its 0.5 mL silicone-free Improject syringe plunger. The new plunger is specifically designed for prefilled syringe...

ARVO Showcases Manufacturers Looking to Refine Ocular Injections

Big ideas typically dominate the headlines, such as AI, gene therapy, or oculomics, but innovation also happens in small things. The 2025 ARVO meeting displayed a surprising amount of attention to ...

Batten Disease Candidate Leads the Way in New Gene Therapy Trials

A presentation by Robert Henderson, MD (UK), on May 8 was a highlight of the many ARVO sessions on gene therapy. Henderson presented interim results from a clinical trial of a gene therapy candidat...

Innovation and Collaboration Take Center Stage at Eyecelerator Meeting

For the first time, an Eyecelerator meeting preceded the ARVO annual conference, convening on May 2 at the Grand Hyatt Deer Valley in Park City, Utah. The event brought together 363 attendees, incl...

Clinical Trial Updates for Ophthalmic Candidates, June 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Emerging Companies Pursuing Ophthalmic Indications, June 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

PDUFA Dates for Ophthalmic Drug Candidates, June 2025

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

June 2025 Ophthalmic News Briefs

Bausch + Lomb announced June 4 the US launch of Blink Nourish and Blink Boost over-the-counter lubricating eye drops. Both products are preservative-free and come in a 10 mL multi-dose bottle. Blin...

NIH Study Determines Brain Circuits Affected by Retinal Cell Loss

Researchers at the National Institutes of Health have determined which vision-processing cells in the brain are affected by damaged retinal ganglion cells (RGCs). Current vision restoration therapi...

US FDA Gives Green Light to Phase II/III Trial of Ocugen’s Stargardt Candidate

Ocugen announced June 16 that the US FDA had cleared an investigational new drug (IND) application for a Phase II/III trial of its OCU410ST subretinal gene therapy candidate for ABCA4-associated re...

Beacon Therapeutics Appoints Daniel Chung, DO, as Chief Medical Officer

Beacon Therapeutics announced June 9 that it had appointed Daniel Chung, DO, as chief medical officer. Chung most recently served as chief medical officer of the ophthalmic gene therapy company Spa...

ViGeneron Rebrands as VeonGen, Gains Rare Pediatric Nod for Stargardt Candidate

Germany’s ViGeneron announced June 5 its rebranding to VeonGen Therapeutics. VeonGen has advanced two gene therapy programs into clinical development—VG801 for Stargardt disease and other ABCA4-rel...

Outlook Launches Lytenava (Bevacizumab) in Germany, UK for Wet AMD

Outlook Therapeutics announced June 2 that it had launched Lytenava (bevacizumab gamma) in Germany and the UK for the treatment of wet age-related macular degeneration (AMD). The company said it wa...

Gore Launches Silicone-Free Plunger for Ophthalmic Prefilled Syringes

Materials company W.L. Gore & Associates announced June 3 the commercial launch of its 0.5 mL silicone-free Improject syringe plunger. The new plunger is specifically designed for prefilled syringe...

Bayer Receives Approval in China for High-Dose Eylea in Wet AMD

German drugmaker Bayer announced May 22 that China’s National Medical Products Administration had granted marketing authorization for high-dose Eylea (aflibercept 8 mg) for the treatment of wet age...

New Scleral Clamp Allows Delivery of Two Cell Grafts in Same Eye for Comparing Effects

Scientists with the National Institutes of Health have shown that a new surgical technique can successfully deliver two cell grafts in adjacent subretinal locations in the same eye—allowing direct ...

US FDA Sets Decision Date of Oct. 21 for Xbrane’s Lucentis Biosimilar Candidate

Sweden’s Xbrane Biopharma announced May 23 that the US FDA had accepted the resubmitted biologics license application (BLA) for its Lucentis (ranibizumab) biosimilar. The FDA set a decision date of...

Deepeye TPS AI Support Tool for Wet AMD Treatment Gains CE Marking

Germany’s Deepeye Medical announced May 21 that its Deepeye TPS artificial intelligence assistant had been granted CE marking in the EU as a Class IIa medical device. The company said medical assis...

US FDA Grants Rare Pediatric Designation to Ocugen’s Gene Therapy Candidate for Stargardt

Ocugen announced May 27 that the US FDA had granted rare pediatric disease designation to its OCU410ST subretinal gene therapy candidate for ABCA4-associated retinopathies, including Stargardt dise...

Dyno Launches New Capsid for Ophthalmic Gene Therapy Developers

Dyno Therapeutics, of Watertown, Massachusetts, has launched a new adeno-associated virus (AAV) capsid for ophthalmic gene therapies, in addition to capsids for neuromuscular and central nervous sy...

US FDA Approves Genentech’s Susvimo Refillable Implant for DR

Genentech, a member of the Roche Group, announced May 22 that the US FDA had approved Susvimo, a refillable ranibizumab implant, for diabetic retinopathy (DR). The South San Francisco, California, ...

Regenxbio Moves to Monetize Future Royalties in Deal Worth up to $250 Million

Gene therapy developer Regenxbio announced May 19 that it had closed a non-dilutive royalty bond agreement worth up to $250 million with Healthcare Royalty (HCRx). The Rockville, Maryland, company ...

US FDA Grants Breakthrough Status to Belite Bio’s Oral Stargardt Candidate

Belite Bio announced May 21 that the US FDA had granted breakthrough therapy status to tinlarebant, an oral tablet targeting Stargardt disease. Sponsor companies receiving breakthrough designation ...

Topcon Healthcare Acquires RetInSight to Advance AI-Powered Imaging in Eye Care

Topcon Healthcare announced May 2 that it had acquired privately held retinal AI analysis company RetInSight, of Austria. No financial details were disclosed. The companies forged a partnership in ...

Select US FDA Approvals and Clearances in April 2025

Device makers gained US FDA clearance for seven technologies through the ophthalmic device division using the 510(k) pathway in April 2025, according to the agency’s database. BVI Medical received ...

Therini Bio Leads Latest Ophthalmic Fundraising with $39 Million in Series A

Therini Bio led recent ophthalmic fundraising efforts with $39 million in Series A funding to advance its lead candidate targeting the inflammatory component of fibrin. Financing announced in the p...

GA Patients in Eyestem Cell Therapy Trial Show Significant Improvement

India’s Eyestem Research reported April 15 that patients with geographic atrophy (GA) in a Phase I trial of its Eyecyte-RPE cell therapy saw significant vision improvement. Eyecyte-RPE is a cryopre...

Alcon Emphasizes Efficiency of Unity VCS and CS Systems at ASCRS Launch

Surgeons attending the 2025 ASCRS meeting in Los Angeles dropped by Alcon’s booth for multiple presentations of the new Unity dual-function and cataract machines, rather than gathering in big numbe...

Unity Bio to Cut Workforce, Seek Strategic Alternatives for UBX1325 in Retina

Unity Biotechnology announced May 5 that it would reduce its workforce and seek an established ophthalmic company to continue the development of intravitreal UBX1325, a Tie2/anti-VEGF bispecific an...

Clinical Trial Updates for Ophthalmic Candidates, May 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Four Eylea Biosimilars Get Q-Codes for Billing Payers in the US

The Centers for Medicare and Medicaid Services (CMS) issued product-specific Q-codes for four Eylea biosimilars during Q4-2024 and Q1-2025. Q-codes are billing codes for reimbursement that are simi...

Emerging Companies Pursuing Ophthalmic Indications, May 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

May 2025 Ophthalmic News Briefs

London’s Okyo Pharma announced April 30 that it would accelerate development of topical urcosimod, formerly OK-101, in neuropathic corneal pain, following early closure of its Phase II trial. The t...

Q1-2025 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, Sight Sciences, ANI, Iridex, and Xbrane

Alcon reported May 13 that its Q1-2025 net sales were $2.45 billion, on par with $2.44 billion in Q1-2024 and up 3 percent on a constant currency basis. Surgical net sales totaled $1.33 billion (do...

Unity Bio to Cut Workforce, Seek Strategic Alternatives for UBX1325 in Retina

Unity Biotechnology announced May 5 that it would reduce its workforce and seek an established ophthalmic company to continue the development of UBX1325, a Tie2/anti-VEGF bispecific antibody candid...

Maximilian Foerst to Lead Carl Zeiss Meditec, as Markus Weber, PhD, Steps Down

Carl Zeiss Meditec announced May 7 that Markus Weber, PhD, the company’s president and CEO, will step down of his own accord, effective May 31. Replacing Weber will be Maximilian Foerst, currently ...

Topcon Healthcare Acquires RetInSight to Advance AI-Powered Imaging in Eye Care

Topcon Healthcare announced May 2 that it had acquired privately held retinal AI analysis company RetInSight, of Austria. No financial details were disclosed. The companies forged a partnership in ...

Q1-2025 Ophthalmic Revenue Roundup for Amgen, Hoya, Apellis, Tarsus, STAAR, RxSight, and Ocular Therapeutix

​ Amgen, of Thousand Oaks, California, reported May 1 that its Q1-2025 revenue from Tepezza was $381 million, a 10 percent decrease from $424 million in Q1-2024. The total consisted of $365 million...

US FDA Grants Marketing Clearance for OcuSciences’ OcuMet Beacon Retinal Imager

OcuSciences, of Ann Arbor, Michigan, announced May 1 that the US FDA had granted marketing clearance for its flagship device, the OcuMet Beacon retinal imager. The 510(k) clearance describes the Oc...

RetinAI and FVS Gain CE Marking for LuxIA DR Screening Algorithm

Switzerland’s RetinAI and Spain’s Fundación Ver Salud (FVS) announced April 30 that LuxIA, their co-developed artificial intelligence algorithm for diabetic retinopathy screening, had received CE m...

US FDA Grants RMAT Status to Opus’ LCA5 Gene Therapy Candidate

Opus Genetics announced May 6 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to OPGx-LCA5, its investigational gene therapy for the treatment of Leber congeni...

US FDA Grants RMAT Status to 4DMT’s Gene Therapy Candidate in DME

4D Molecular Therapeutics announced May 1 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to 4D-150, an intravitreal gene therapy candidate for diabetic macula...

Q1-2025 Ophthalmic Revenue Roundup for Roche, Regeneron, AbbVie, Glaukos, Lumibird, and Biogen

Swiss company Roche reported April 24 that Vabysmo sales in Q1-2025 were CHF 1 billion ($1.1 billion, calculated March 31, 2025), up 18 percent in constant currency from CHF 847 million in Q1-2024....

GA Patients in Eyestem Phase I Cell Therapy Trial Show Significant Vision Improvement

India’s Eyestem Research reported April 15 that patients with geographic atrophy (GA) in a Phase I trial of its Eyecyte-RPE cell therapy saw significant vision improvement. Eyecyte-RPE is a cryopre...

Four Eylea Biosimilars Get Q-Codes for Billing Payers in the US

The Centers for Medicare and Medicaid Services (CMS) issued product-specific Q-codes for four Eylea biosimilars during Q4-2024 and Q1-2025. Q-codes are billing codes for reimbursement that are simi...

Alcon Rolls Out Unity VCS and CS Systems at ASCRS Meeting

Alcon announced April 25 the launch of its dual-function Unity Vitreoretinal Cataract System (VCS) and stand-alone Unity Cataract System (CS) in four markets, including the US. The announcement cam...

US FDA Rejects Regeneron’s sBLA for Eylea HD Dosing Interval Beyond 16 Weeks

Regeneron announced April 18 that the US FDA had issued a complete response letter rejecting the company’s supplemental biologics license application (sBLA) to add extended dosing intervals up to e...

May 12 is Deadline to Apply for Ramin Tadayoni Award for Research

Applications are open until May 12, 2025, for this year’s Ramin Tadayoni Award, offered by the European Society of Retina Specialists, or Euretina, and supported by Oculis as a tribute to retina sp...

US FDA Accepts Outlook’s Resubmitted BLA for Lytenava, Sets PDUFA Date of Aug. 27

Outlook Therapeutics announced April 8 that the US FDA had accepted the resubmitted biologics license application (BLA) for ONS-5010 (bevacizumab-vikg, Lytenava), an ophthalmic formulation of bevac...

Retina Pharma and Premium IOLs Continue to Drive Ophthalmic Market

The ophthalmology industry produced an estimated $48.8 billion in revenue in 2024, with an expected compound annual growth rate (CAGR) of 4.5 percent. Market Scope estimates the industry will reach...

Opthea Discontinues Wet AMD Program After Second Phase III Trial Misses Endpoint

Opthea announced March 31 its decision to discontinue development of sozinibercept (OPT-302) in wet age-related macular degeneration (AMD) after a second Phase III trial missed its primary endpoint...

Clinical Trial Updates for Ophthalmic Candidates, April 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Emerging Companies Pursuing Ophthalmic Indications, April 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Biocon’s Deal with Regeneron Will Bring Yesafili to Market in US No Later than H2-2026

India’s Biocon Biologics reported April 15 that it had reached a settlement and license agreement with Regeneron that clears the way for Biocon to commercialize Yesafili, a biosimilar to Eylea, in ...

Thomas Panek Becomes President, CEO of Lighthouse Guild

Lighthouse Guild announced March 18 that it had appointed Thomas Panek as its new president and CEO, effective April 1. Panek replaced Calvin Roberts, MD, who had led the nonprofit since April 2020...

April 2025 Ophthalmic News Briefs

Carl Zeiss Meditec announced March 21 the availability in Canada of the Visulas Combi, a green and YAG ophthalmic laser workstation combining photodisruption, photocoagulation, and slit lamp techno...

Biocon Reaches Settlement, License Agreement with Regeneron to Bring Yesafili to Market in US

India’s Biocon Biologics reported April 15 that it had reached a settlement and license agreement with Regeneron that clears the way for Biocon to commercialize Yesafili, a biosimilar to Eylea, in ...

Opthea Will Lay Off 65 Percent of Employees after Phase III Wet AMD Failures

Opthea plans to lay off about 65 percent of its workforce, effective May 1, the company said in a corporate update filed April 10 with the with the US Securities and Exchange Commission (SEC). The ...

US FDA Grants RMAT Status to Atsena’s X-Linked Retinoschisis Gene Therapy Candidate

Atsena Therapeutics announced April 15 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to ATSN-201, its gene therapy candidate for X-linked retinoschisis (XLRS...

US FDA Accepts Outlook’s Resubmitted BLA for Lytenava, Sets PDUFA Date of Aug. 27

Outlook Therapeutics announced April 8 that the US FDA had accepted the resubmitted biologics license application (BLA) for ONS-5010 (bevacizumab-vikg, Lytenava), an ophthalmic formulation of bevac...

Opthea Discontinues Wet AMD Trials After Second Phase III Trial Misses Endpoint

Opthea announced March 31 its decision to discontinue development of sozinibercept (OPT-302) in wet age-related macular degeneration (AMD) after a second Phase III trial missed its primary endpoint...

2024 Ophthalmic Revenue Roundup for Harrow, Astellas, Iridex, and Xbrane

Nashville, Tennessee-based Harrow reported March 27 that its 2024 revenue was $199.6 million, a 53 percent increase over $130.2 million in 2023. The company generated record quarterly revenue in Q4...

Aviceda Appoints Jeffrey Nau, PhD, MMS, as Chief Executive Officer

Aviceda Therapeutics announced April 1 that it had appointed Jeffrey Nau, PhD, MMS, as chief executive officer, effective immediately. Nau will also join the company’s board of directors, Aviceda s...

Opthea, Unity Candidates Miss Clinical Trial Endpoints vs. Aflibercept

Opthea and Unity Biotechnology reported results March 24 for their retinal treatment candidates that failed to meet or beat Regeneron’s Eylea (aflibercept) in clinical trials for wet AMD and DME, r...

Chinese Regulators Approve DORC’s ILM-Blue Ocular Dye

German company Carl Zeiss Meditec announced March 27 that China’s National Medical Products Administration (NMPA) had approved ILM-Blue ocular dye from DORC. The product is approved in the US as Ti...

Surrozen to Focus on Ophthalmic Pipeline, Raises up to $175 Million in Private Placement

Surrozen announced March 24 that it would focus on its ophthalmic pipeline, including the development of new treatment options for retinopathies. Concurrently, the company said that a private place...

Zeiss Launches Visulas Combi in Canada

Carl Zeiss Meditec announced March 21 the availability in Canada of the Visulas Combi, a green and YAG ophthalmic laser workstation combining photodisruption, photocoagulation, and slit lamp techno...

US FDA Expands Label for Iluvien to Include Chronic Non-infectious Posterior Uveitis

ANI Pharmaceuticals, of Baudette, Minnesota, announced March 14 that the US FDA had approved an expanded label for Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) to include treatment...

Thomas Panek to Lead Lighthouse Guild

Lighthouse Guild announced March 18 that it had appointed Thomas Panek as its new president and CEO, effective April 1. Panek replaces Calvin Roberts, MD, who has led the nonprofit since April 2020...

Xbrane to Sell Part of Company to Alvotech, Plans to Keep Ximluci

Sweden’s Xbrane will sell its Cimzia biosimilar candidate and parts of its organization to Iceland’s Alvotech for SEK 275 million ($27.1 million), the two companies reported March 20. Xbrane will r...

Vivani Now Intends to Spin Out Cortigent, Developer of Orion Implant

Vivani Medical, of Alameda, California, reported March 12 that it intends to spin off its Cortigent neurostimulation business, formerly Second Sight Medical Products, into a fully independent, publ...